Healthcare / Diagnostics / Signal Release

Press Release

The Reagent Is the Product and the Instrument Is a Financing Arrangement — Sysmex Books 61.58 Per Cent of Revenue as Reagents, bioMérieux 83.38, and the Spread Decides What a Price Cut Does

· Healthcare

Pheonix Research has published Global IVD Reagents and Consumables Market Report, Size, Share and Forecast 2026–2033: The Instrument Is a Financing Arrangement, which measures the consumable layer of in vitro diagnostics at USD 78,400 million in 2025 — 74.74 per cent of the USD 104.9 billion IVD base — reaching USD 118,600 million by 2033 at a compound annual rate of 5.31 per cent, an increment of USD 40,200 million, or 1.51 times the base year. The full report is available at pheonixresearch.com.

The finding is that the razor-and-blade ratio is not a property of the industry. It is a property of the contract. Two companies sell closed instruments into the same kind of laboratory, are paid per test, and disclosed reagent shares in the same year of 61.58 per cent and 83.38 per cent — a 21.8-point spread produced almost entirely by how each books the instrument. Because the reagent is where the margin sits, the reagent is what gets tendered: Anhui’s 28-province alliance bought tumour-marker and thyroid-function reagents across 25 sub-categories and 5,978 winning records at an average reduction of 52.6 per cent, on a two-year term executing from 1 March 2026. You cannot tender an analyser. You tender what goes into it.

Two companies, the same instrument, a 21.8-point disagreement about what business they are in

Sysmex, in the year to March 2026: reagents JPY 307,923 million, instruments JPY 103,232 million, service JPY 69,275 million, other JPY 19,575 million, total JPY 500,006 million. Reagents are 61.58 per cent of net sales; reagents, service and consumables together are 79.35 per cent. Its own twenty-year series makes the point better than any table: ongoing sales rose from 66.4 per cent to 79.5 per cent of revenue, a 13.1-point drift in the direction of the annuity.

bioMérieux, calendar 2025: reagents EUR 3,393.2 million, equipment EUR 282.3 million, services EUR 254.1 million, equipment rentals EUR 61.9 million, other revenue EUR 78.3 million, total EUR 4,069.8 million. Reagents are 83.38 per cent of revenue. Equipment is 6.94 per cent.

Both sell a closed system. Both are paid per test. Both put the same physical chemistry in front of the same bench. The difference is that bioMérieux rents its instruments and books the reagent share embedded in that rental as rent — its own note says the equipment-rental line includes revenue reclassified from reagents — while Sysmex sells analysers outright and books them as instruments.

That matters because the ratio decides what a price cut does to a profit and loss account. A vendor at 83 per cent reagent content takes an administered reduction on 83 per cent of revenue with its instrument cost already committed. A vendor at 62 per cent takes it on 62, and still has an instrument line it can price, bundle or place at a margin. The same tender, two different outcomes, fixed before the tender is announced.

The layer is 74.74 per cent of in vitro diagnostics, and it is not a segment

Summed with the instrument and service layer — USD 26,492 million, 25.26 per cent — the layer equals the USD 104.9 billion IVD base exactly. It is additive with the instruments and not additive with the four discipline reports published underneath the same hub, each of which measures a whole discipline including its analysers. Summing this report with immunoassay would count the reagent twice, and the report states that on the page rather than in a footnote.

Its share of the base falls from 74.74 per cent to 71.93 per cent by 2033, because instruments, software and services grow faster than the consumable they carry.

Product class 2025 (USD m) 2033 (USD m) CAGR Share of 2025 base
Immunoassay reagents 21,638 30,900 4.55% 27.60%
Molecular diagnostics consumables 15,994 29,600 8.00% 20.40%
Clinical chemistry reagents 11,760 14,900 3.00% 15.00%
Point-of-care cartridges and strips 7,605 12,100 5.98% 9.70%
Microbiology and ID/AST consumables 6,978 10,600 5.37% 8.90%
Haematology and coagulation reagents 5,880 8,200 4.25% 7.50%
Histology and pathology consumables 3,998 5,900 4.98% 5.10%
Quality-control materials and calibrators 2,666 3,900 4.87% 3.40%
General laboratory consumables 1,881 2,500 3.62% 2.40%
Total 78,400 118,600 5.31% 100.00%

Volume compounds at 6.00 per cent and value at 5.31 — the gap is the price

Global IVD reportable tests run from 47,300 million in 2025 to 75,400 million in 2033, a 6.00 per cent compound rate, against 5.31 per cent for the value of the layer. Realised reagent revenue per test therefore falls from USD 1.657 to USD 1.573, minus 5.1 per cent across the window and minus 0.65 per cent a year. That drift is mild next to clinical chemistry’s minus 1.3 per cent, and the reason is mix: as molecular consumables and point-of-care cartridges take share, the average basket moves toward products whose price is not yet administered.

The average is improving while the individual lines inside it deteriorate. That is the most dangerous kind of stability in a forecast, and it is why the sensitivity table carries a 127-basis-point band rather than a point estimate.

You cannot tender an analyser. You can tender what goes into it.

A reagent reaches a laboratory through one of three mechanisms, and they act on different lines of the same profit and loss account.

The reagent is tendered, in China. Anhui’s alliance, led by the provincial healthcare security administration and joined by 28 provinces, bought tumour-marker reagents across 16 items and thyroid-function reagents across 9, producing 25 sub-categories and 5,978 winning records at an average reduction of 52.6 per cent on a two-year term, executing in Yunnan from 1 March 2026. Roche, Abbott and Siemens all appear among the winners — a reminder that a vendor can win a tender and still lose revenue. In 2025 the policy moved into the volume base: Gansu led the first procurement of routine blood, stool and urine reagents and strips, and Anhui extended to cardiac markers. Routine chemistry and haematology reagents are 22.50 per cent of this layer, and they are now in scope.

The test is administered and the reagent is not, in the United States. Medicare prices the CPT code; the laboratory buys its reagents privately. The preliminary calendar 2027 clinical laboratory fee schedule cut chemistry 16 per cent across 387 codes and capped annual reductions at 15 per cent for 2027–2029 — a cap that defers the remainder rather than forgiving it, and which tells you the underlying medians sit further below current rates than one year can reach. Deflation arrives at the output price while the input price is negotiated, so a laboratory absorbs it as margin compression rather than passing it upstream.

Neither is published, in most of Europe and most of Asia-Pacific. Framework agreements, distributor margins and local-manufacture criteria. The same 4.55 per cent growth in immunoassay reagents is produced by three completely different mechanisms in three regions, and only the Chinese one starts with the reagent.

So the instrument becomes the growth product, and the engineering works against the reagent

Snibe published the inversion in one set of accounts for 2025. Domestic reagent revenue fell 13.77 per cent while chemiluminescence reagent volume rose 3.20 per cent and domestic instrument revenue rose 6.88 per cent, with 1,462 analysers installed domestically. Overseas, where the reagent price is negotiated rather than administered, reagent revenue rose 34.96 per cent on volume up 43.57 per cent, carried by 3,357 installed analysers. The same company, in the same year, sold the razor where the blade is priced and sold the blade where it is not.

But the product development points the other way, and this is the part of the thesis that cannot be marketing. Snibe’s flagship chemistry analyser is specified at 2,000 tests per hour, 3,000 with the electrolyte module, on what the company describes as an ultra-micro reaction system with on-board dilution of concentrated reagent — and the stated benefit is a significant reduction in reagent and sample consumption. Every generation of instrument reduces the vendor’s own reagent revenue per installed analyser. That is the correct engineering answer and the wrong revenue answer, and it is why placement has to keep growing for a reagent-led business to grow at all. The 6.00 per cent against 5.31 per cent gap is that sentence in arithmetic.

Twenty per cent of the base supplies a third of the growth

Of the USD 40,200 million the layer adds, molecular consumables supply USD 13,606 million — 33.85 per cent — from 20.40 per cent of the base, compounding at 8.00 per cent. Immunoassay reagents supply USD 9,262 million (23.04 per cent) at 4.55. Point-of-care cartridges USD 4,495 million (11.18 per cent) at 5.98. Microbiology and ID/AST USD 3,622 million (9.01 per cent) at 5.37. Clinical chemistry USD 3,140 million (7.81 per cent) at 3.00, from a 15.00 per cent base.

The mechanism is the same in every case: a cartridge’s price sits inside a device contract, while a reagent’s price sits in a room with 28 provinces in it. Flow cells, library-preparation kits and amplification chemistry are priced against a menu that is still expanding and a buyer who is not yet being tendered.

48.76 per cent attributes, 51.24 per cent does not — and that is not a research gap

Nine disclosed or estimated pools total USD 38,228 million, 48.76 per cent of the layer, leaving a stated residual of USD 40,172 million, 51.24 per cent. It is the largest residual in this cluster, and it is the mirror image of haematology, where 87.72 per cent attributes to named vendors against a 12.28 per cent residual. A six-part differential cannot be assembled from third-party reagents, so no unlisted middle can exist. A reagent is a formulation: the physical fit is proprietary, the chemistry is not.

The intensities are printed rather than buried, because four of the five largest diagnostics companies in the world publish no reagent split at all: Roche 64 per cent of CHF 13,847 million, Danaher 80 per cent of USD 9,941 million, Abbott 78 per cent of USD 8,937 million, Siemens Healthineers 72 per cent of EUR 4,347 million, QuidelOrtho 70 per cent of USD 2,730 million, Bio-Rad 90 per cent of USD 1,562.1 million. Two are disclosed outright — bioMérieux’s reagent line and Sysmex’s — and one, Snibe, discloses overseas reagent revenue and estimates domestic at 80 per cent.

The margin says which half of the pair is protected

Danaher’s Diagnostics segment reported USD 9,941 million of revenue and USD 2,650 million of segment operating profit — 26.66 per cent — against 26.8 per cent in 2024, on core growth of 1.5 per cent. A business that is roughly four-fifths recurring consumables held its margin flat while its Chinese reagent prices were being reset by procurement.

Sysmex, in the same cycle, took sales down 1.7 per cent and operating profit down 40.8 per cent, with margin falling from 17.2 to 10.4 per cent — a 61.58 per cent reagent ratio, a large Japanese and Chinese installed base, and the same tender landing on both.

Roughly sixteen points of operating margin separate the two, through the same policy event. The difference is not product quality. It is what share of the profit and loss account is protected by an installed base that must buy.

The one consumable that cannot be declined is quality control. Bio-Rad’s Clinical Diagnostics segment grew 0.8 per cent at constant currency to USD 1,562.1 million with quality controls named among its drivers, in the same year and the same segment where lower reimbursement for diabetes testing in China was named as the offset. A laboratory can defer an analyser, renegotiate a reagent price or send a test out. It cannot stop running the controls that validate the result it reports.

The risk is not demand, and the volume risk is the worse one

Snibe attributes its domestic decline to three policies acting together: provincial reagent procurement, the deepening of DRG/DIP per-case payment, and test-panel unbundling with mutual recognition of results across institutions. The first is a price risk. The others reduce the number of tests performed per patient, because a panel ordered as a set is ordered item by item and a result produced at one institution need not be produced again at another.

A volume risk is worse than a price risk here, because the instrument commitment is fixed. A vendor that has placed an analyser on a five-year reagent commitment has already paid for volume that may not arrive.

Scenario 2033 value (USD m) CAGR
Procurement extends to routine chemistry, cardiac and haematology across twelve more provinces 112,900 4.66%
Panel unbundling and cross-institution result recognition cut Chinese test volume 8% 115,400 4.95%
Base case 118,600 5.31%
Installed-base placement outpaces price 121,200 5.60%
No further reagent procurement after the announced alliances 124,300 5.93%

The band is 127 basis points wide. Almost all of it is two governments and one hospital-payment reform. Nothing in it is a clinical or demographic assumption, which is the point: this is the one layer of in vitro diagnostics where the forecast is mostly a policy forecast.

Regulation adds a second, slower cost. Registration is granted per reagent, not per instrument. Under IVDR as amended by Regulation (EU) 2024/1860 the transition runs to 31 December 2027 for Class D, 31 December 2028 for Class C and 31 December 2029 for Class B and Class A sterile, and each step adds notified-body review, technical documentation and post-market surveillance to every individual item. Snibe holds 288 certificates to sell 201 chemiluminescence reagents — 1.43 per item. That is a barrier for a large vendor and a wall for a small one, which means the 51.24 per cent residual consolidates. The effect on price is the opposite of the effect on competition: fewer suppliers, less pressure.

Currency sits underneath it. The layer is reported in USD on a converted basis at JPY 148, EUR 1.13 and CHF 1.15 to the dollar, so a 10 per cent move in the yen changes Sysmex’s converted reagent revenue by roughly USD 200 million without a single test changing hands.

What not to underwrite

Do not underwrite price. Realised revenue per test falls from USD 1.657 to USD 1.573 and every scenario in the sensitivity table is a variation on how fast that happens. A model that grows this layer by growing revenue per test overstates 2033 by roughly the entire molecular consumables increment.

Do not underwrite instrument revenue as a proxy for the franchise. Danaher grew Diagnostics core revenue 1.5 per cent and held 26.66 per cent because four-fifths of the revenue was recurring; Sysmex’s sales fell 1.7 per cent and its operating margin halved. The two numbers measure the same industry from opposite sides of the razor-and-blade ratio, and only one of them is a valuation input.

Do not read 2025’s transactions as capacity purchases. QIAGEN completed the acquisition of Parse in December 2025 while discontinuing NeuMoDx and Dialunox at a cost of roughly USD 20 million of 2025 revenue — a menu purchase and a platform exit in the same year. Danaher’s cartridge installed base stands above 60,000 instruments carrying more than 30 cleared assays. The scarce asset in this market is not innovation. It is the right to be on the bench.

Scope and method

Nine product classes are in scope: assay reagents and kits, calibrators and controls, quality-control materials, single-use cartridges and strips, blood-culture bottles and AST panels, culture media, histological stains and antibodies, slides and cassettes, and specimen-collection consumables. Instruments, analysers, track systems, middleware, software and service are excluded and sized only as the remainder.

The report is built at a 70 per cent secondary and 30 per cent primary split. The secondary layer is audited results, statutory filings and government procurement notices read from the issuing body — Sysmex’s net-sales-by-product-type series, bioMérieux’s IFRS 15 revenue-by-category note, Danaher’s FY2025 results and Form 10-K, Bio-Rad’s FY2025 results and Form 10-K, Snibe’s 2025 Annual Report as filed on cninfo, the Anhui-led alliance’s awards as executed by the Yunnan Provincial Healthcare Security Administration, and the CMS preliminary CY 2027 fee schedule. The primary programme comprised 52 depth interviews across 14 markets, 31 open-ended interviews conducted around reagent tender cycles, a 191-respondent laboratory survey and observation at AACC, EuroMedLab, the Chinese Laboratory Medicine Congress and MEDICA. Primary work establishes mechanism and carries no figure. Foreign exchange is on the cluster basis: EUR 1.13, CHF 1.15, JPY 148 and RMB 7.20 to the dollar. The report contains no third-party market-research citations.

Companion analysis

About this report

The full report — with market definition and scope, executive summary, market size construction and attribution, product segmentation across nine classes of consumable, regional structure, end-market and channel structure, price formation across three regimes, volume and test economics, competitive landscape, value chain and margin distribution, technology and innovation, investment activity, market risk and sensitivity, regulatory landscape, and research methodology and sources — is available at https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-ivd-reagents-and-consumables-market/.

About Pheonix Research

Pheonix Research is a market intelligence platform that queries a live graph of more than 500 nodes across 25 industrial sectors to surface leading signals and translate them into role-specific decisions. Its premise is that companies operate in value chains rather than industries, and that a signal is only useful when it arrives with the context and the window to act on it.